Year: 2025

Disclosure of trading in own shares occurred from October 28 to October 31, 2025 Saint-Cloud, November 4, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from October 28 to October 31, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders’ Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation:Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code)ELIS SA 969500UX71LCE8MAY492 10/28/2025 FR0012435121 20,000 24.9893 XPARELIS SA 969500UX71LCE8MAY492 10/28/2025 FR0012435121 8,900 24.9844 CEUXELIS SA 969500UX71LCE8MAY492 10/28/2025 FR0012435121 600 25.0200 TQEXELIS...

Coloplast A/S – Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%.• EBIT1,2 was DKK 7,670 million, a 5% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.• Adjusted3 net profit before special items was DKK 5,148 million, a DKK 123 million increase from last year. Adjusted3 diluted earnings per share (EPS) before special items increased by 2% to DKK 22.84.• Special items expenses amounted to DKK 469 million, related to profitability improvement initiatives, including the Skin Care divestment, management restructuring and the...

Ad hoc announcement pursuant to Art. 53 LRComparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroidsPratteln, Switzerland, November 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today reported positive topline results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating AGAMREE® (vamorolone) in patients with Duchenne muscular dystrophy (DMD). The long-term analysis included corticosteroid-naïve patients who began AGAMREE treatment between four and seven years of age...

2024/25Full year financial results 1 October 2024 – 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%.• Growth in Ostomy Care was broad based with good contribution from recent product launches and led by Europe and Emerging Markets ex. China. Sales in China declined due to the worsened consumer sentiment and increased competitive pressures.• Growth in Continence Care was driven by continued strong contribution from Luja™ for both male and female users.• Voice & Respiratory Care growth was driven by continued good...

Reference is made to the stock exchange announcement made by Zelluna ASA (the “Company”) on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the “Private Placement”), divided on a first tranche of 3,729,774 new shares (“Tranche 1”) and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the “Retail Offering”).  Radforsk Investeringsstiftelse (“Radforsk”) holds 2,469,693 shares in the Company, representing 12.07% of the total number of shares and votes in the Company. Pursuant to a share lending agreement entered into in connection with the Private Placement and the Retail Offering, Radforsk has lent 742,289 existing shares to the manager for the...

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patientsV-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patientsLp(a) data underscore importance of early detection of this independent CVD risk factor in premature ASCVD patients and potential benefit of Lp(a)-targeted therapiesBasel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney...